Investment Rating - The report assigns an "Accumulate-A" investment rating to the company with a target price of 30.19 CNY for the next six months [3]. Core Insights - Chengda Biological has established itself as a leader in the rabies vaccine market, maintaining a dominant position for over a decade. The company's growth is expected to be driven by three main factors: increasing market share of existing products, commercialization of its research pipeline, and the strategic initiatives following the indirect control by Guangdong Min Investment [1][7]. - The company has a robust product matrix, with its rabies vaccine and inactivated Japanese encephalitis vaccine being the primary revenue sources. Recent years have seen performance pressures due to intensified competition [2][24]. - The research pipeline is rich, with several vaccines, including the human diploid rabies vaccine and quadrivalent influenza vaccine, set for registration applications in the coming years [3][21]. Summary by Sections 1. Company Overview - Chengda Biological has been focused on the vaccine sector for over 20 years, with its core product, the human rabies vaccine, launched in 2005. The company has maintained a leading market share since 2008 [1][13]. - The company also offers the only inactivated Japanese encephalitis vaccine available in China, which has seen significant marketing efforts to enhance its market penetration [2][24]. 2. Product Matrix - The rabies vaccine produced using Vero cells is the leading product, with a stable and efficient production process. The company has also initiated the application for the human diploid rabies vaccine [2][41]. - The inactivated Japanese encephalitis vaccine has been upgraded and is expected to see significant growth from 2022 to 2024 due to increased academic promotion and brand awareness [2][24]. 3. Research Pipeline - The company has a well-stocked research pipeline, with multiple vaccines in various stages of development, including the human diploid rabies vaccine and several influenza vaccines [3][21]. - The 15-valent HPV vaccine is set to enter Phase II clinical trials in March 2025, while other vaccines are progressing through different clinical trial phases [3][21]. 4. Shareholder Empowerment - The governance structure of Chengda Biological has been significantly enhanced following the indirect control by Guangdong Min Investment, which is expected to facilitate innovation and investment opportunities [7][15]. - The company has announced several investment initiatives, including the establishment of a wholly-owned subsidiary for innovative drugs and a biopharmaceutical investment fund, aiming to create a dual-driven business model of "vaccines + innovative drugs" [7][8]. 5. Financial Forecast and Valuation - The company is projected to achieve revenues of 1.39 billion CNY, 1.48 billion CNY, and 1.59 billion CNY for the years 2025, 2026, and 2027, respectively, with net profits of 131 million CNY, 141 million CNY, and 177 million CNY [8][9].

Core Viewpoint - Watson Bio expects to achieve revenue of 2.4 billion to 2.43 billion yuan and a net profit attributable to shareholders of 160 million to 190 million yuan in 2025, reflecting a year-on-year growth of 13% to 34% [2] Group 1: Financial Performance - The company anticipates a narrowing decline in domestic vaccine product revenue and continuous growth in international vaccine product revenue, with export vaccine revenue increasing by approximately 35% compared to the previous year [2] - Operational management capabilities have improved due to ongoing cost reduction and efficiency enhancement measures, contributing to the growth in net profit [2] Group 2: International Expansion - By the end of 2025, Watson Bio's vaccine products have been exported to 24 countries and regions, with a successful entry into the Latin American market for its core product, the 23-valent pneumonia vaccine [2] - The company is advancing over 30 international product registration projects covering around 20 countries, including core products like pneumonia and HPV vaccines, laying a solid foundation for sustained overseas revenue growth [2] Group 3: Innovation and R&D - Watson Bio maintains a high level of investment in innovative vaccine research and development, collaborating with renowned universities and research institutions to integrate resources and accelerate the development of multiple innovative vaccines [4] - The company has established an mRNA vaccine technology platform in collaboration with Fudan University and Shanghai Bluebird Biopharmaceuticals, with several mRNA vaccines receiving clinical trial approval [3][4] - The competitive nature of the vaccine industry necessitates continuous strengthening of core technological barriers and operational optimization through an "innovation + management" dual-drive model [4]

Group 1 - The core viewpoint of the article highlights the recent advancements in the domestic vaccine industry, supported by favorable policies, indicating a significant demand for flu and related vaccines due to a notable increase in flu activity, reaching the highest level in three years [1] - The focus is on structural opportunities in flu vaccines, pneumococcal vaccines, and shingles vaccines, with innovation and internationalization being identified as core competitive advantages for vaccine companies in the long term [1] - The vaccine ETF (159643) tracks the vaccine biotechnology index (980015), which selects listed companies involved in bioproducts, life science tools, and services, emphasizing firms engaged in vaccine research, production, and related services [1] Group 2 - The constituent stocks of the index exhibit significant innovation and growth characteristics, reflecting the overall performance and technological development dynamics of the vaccine and biotechnology industry [1]

首针仪式顺利举行，携手共建健康澳门 12月4日，该疫苗在澳门银葵医院成功举行首针接种仪式。活动向澳门各界传递了"主动健康、积极预 防"的理念，也生动诠释了我公司"让中国用上全球创新疫苗，让世界用上中国优质疫苗"的企业愿景。 公司海外业务负责人在致辞中表示："我们非常荣幸能将这款先进的亚单位流感疫苗带给澳门同胞。此 次合作不仅是市场拓展的突破，更是我们实现让世界用上中国优质疫苗愿景的重要一步。我们将持续支 持澳门公共卫生事业，共同守护澳门居民的健康"。 持续创新，迈向更广阔的国际舞台 国际化战略迈出关键一步 近日，中慧生物-B(02627)自主研发的四价流感病毒亚单位疫苗——慧尔康欣顺利运抵澳门特别行政区 并完成通关，成功实现首次出口，正式进入澳门市场。这不仅是公司科研实力与生产质量获得国际认可 的重要标志，更是公司推进全球化布局的关键里程碑。 此次供应澳门的四价流感病毒亚单位疫苗（慧尔康欣），采用先进的第三代流感疫苗技术，包含两种甲 型与两种乙型流感病毒的主要表面抗原，具有纯度高、安全性好、免疫原性强等特点。与传统疫苗相 比，该产品进一步优化了工艺，显著提升了接种安全性与防护效果，适合包括高风险人群在内的各类 ...

Core Viewpoint - Watson Bio (300142) emphasizes its commitment to comply with shareholder information disclosure regulations and aims to build a self-sufficient vaccine industry in China while supplying high-quality products to the global market [1] Group 1: Company Strategy - The company is increasing resource investment across various areas including talent development, project introduction, market marketing, international product registration, clinical trials, international certification, and cooperative production to diversify its international business [1] - Watson Bio is exploring new cooperation models based on its extensive experience to deepen and broaden overseas collaborations, aiming to make innovative vaccines accessible to more people [1] Group 2: Market Positioning - The company aims to enhance its influence in the international market and contribute to global vaccine accessibility [1] - Investors are encouraged to follow the company's announcements for updates on product exports and overseas collaborations [1]

Core Viewpoint - Watson Bio has made significant progress in its strategic layout in the Middle East by obtaining a drug registration certificate for its 13-valent pneumococcal polysaccharide conjugate vaccine from the Jordan Food and Drug Administration [1] Group 1 - The vaccine produced by Watson Bio's subsidiary, Yuxi Watson Bio Technology Co., Ltd., has received the drug registration certificate in Jordan [1] - This marks an important breakthrough in the internationalization process of Watson Bio's 13-valent pneumococcal polysaccharide conjugate vaccine [1] - The actual market launch time and sales performance of the vaccine in Jordan remain uncertain [1]

Group 1 - The company is actively pursuing WHO PQ certification for its nine-valent HPV vaccine, aiming to expand its global market presence [1] - The company plans to leverage the international achievements of its bivalent HPV vaccine to build a broader global network [1] - The company is exploring long-term opportunities in international markets, including Europe and the United States, while supporting the global strategy to eliminate cervical cancer [1]

Core Viewpoint - The article highlights the rapid IPO of Zhonghui Biotech, which achieved a listing on the Hong Kong Stock Exchange in just 10 months, setting a record for the fastest project handled by intermediary institutions [2][4]. Company Overview - Zhonghui Biotech, founded by An Youcai, is a newcomer in the vaccine industry, having been established only 10 years ago and currently offering one vaccine on the market [2][6]. - The company’s flu vaccine is the only quadrivalent subunit vaccine available in the domestic market, priced at 319 yuan per dose, making it the most expensive flu vaccine in China [10][11]. Financial Aspects - The IPO raised approximately 383 million HKD, which will alleviate the company's financial pressure, especially as it faces a bank loan repayment of about 400 million yuan within a year [4]. - As of the end of Q1 2025, Zhonghui Biotech had a cash balance of only 115 million yuan [4]. Market Position and Strategy - Zhonghui Biotech aims to position itself as an international company focused on innovation in the vaccine sector, distinguishing itself from competitors by not participating in the price-cutting trend for flu vaccines [3][10]. - The company is expanding its market reach internationally, particularly targeting Southeast Asia and Latin America, and has formed a strategic partnership with Watson Bio for overseas sales [11]. Product Development - Currently, Zhonghui Biotech has 11 vaccines in its pipeline, with 10 in development and one already on the market [10]. - The company is also working on a human diploid rabies vaccine and other products aimed at replacing imported vaccines and leading globally in vaccine technology [12][13]. Leadership and Expertise - An Youcai, the founder, transitioned into the vaccine industry from a non-biological background, leveraging 15 years of entrepreneurial experience to enhance his expertise in immunology and vaccine development [6][8]. - The company has attracted experienced scientists to its team, including those who have previously worked on significant vaccine projects [7].

Core Viewpoint - Zhifei Biological's 26-valent pneumococcal conjugate vaccine (PCV26) has initiated Phase I clinical trials in Australia, marking a significant step in enhancing the global influence of Chinese vaccines [1] Group 1: Vaccine Development - The PCV26 is the only high-valent vaccine developed independently in China that has entered clinical trials [1] - The vaccine is progressing smoothly in domestic clinical trials, indicating strong development capabilities [1] Group 2: Market Positioning - The PCV26 is expected to synergize with Zhifei's existing 23-valent pneumococcal polysaccharide vaccine and the 15-valent pneumococcal conjugate vaccine, covering the entire age spectrum from infants to the elderly [1] - This strategic positioning aims to enhance Zhifei's status in the global pneumococcal vaccine market [1] Group 3: International Expansion - The initiation of overseas clinical trials signifies a multi-dimensional upgrade in Zhifei's pneumonia product matrix, establishing a more complete and competitive product system [1] - This move is a solid step towards internationalization, laying a stable foundation for market expansion and deepening in the global arena [1]

Core Viewpoint - Wantaibio is actively advancing the WHO PQ certification process for its nine-valent HPV vaccine following its approval, leveraging its existing international achievements with the two-valent HPV vaccine [1] Group 1 - The company has initiated a structured plan for nationwide bidding and procurement work for the nine-valent HPV vaccine after its approval [1] - Wantaibio is confident in accelerating the overseas access and expansion of the nine-valent HPV vaccine, supported by its global network and prior success in over 20 countries with its two-valent HPV vaccine [1] - The two-valent HPV vaccine has been included in immunization programs in eight countries, showcasing the company's established international presence [1]